{"gene":"MTARC2","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":2011,"finding":"MOSC2 (MTARC2) is exclusively localized to the outer mitochondrial membrane in rat liver, as demonstrated by subcellular fractionation of purified outer mitochondrial membranes. Direct binding of a radiolabeled benzamidoxime substrate to MOSC2 was shown. siRNA-mediated knockdown of MOSC2 and mitochondrial cytochrome b5 type B (CYB5B) significantly inhibited amidoxime reductase activity in differentiated 3T3-L1 adipocytes, whereas knockdown of MOSC1, CYB5A, CYB5R1, CYB5R2, or CYB5R3 had no effect. Knockdown of MOSC2 caused impaired lipid synthesis in adipocytes.","method":"Subcellular fractionation, radiolabeled substrate binding assay, siRNA knockdown with enzymatic activity readout and lipid synthesis measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (fractionation, direct substrate binding, siRNA knockdown with functional readouts) in a single rigorous study establishing localization, binding partner identity, and cellular function","pmids":["22203676"],"is_preprint":false},{"year":2013,"finding":"Both mARC1 and mARC2 (MTARC2) are capable of reducing N-hydroxylated substrates (amidoximes) in cellular metabolism, as demonstrated by RNAi knockdown in two human cell lines (HEK-293 and HeLa). The mitochondrial isoform of cytochrome b5 (CYB5B) is an essential electron transport component of the mARC-containing N-reductase system in human cells; the microsomal isoform CYB5A does not participate. The contribution of CYB5B strictly depends on heme, as shown with heme-free apo-CYB5.","method":"RNAi knockdown in human cell lines (HEK-293, HeLa), CYB5A knockout mice, heme-free apo-CYB5 reconstitution assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal knockdown experiments in two cell lines plus knockout mouse plus biochemical reconstitution with functional readouts","pmids":["23703616"],"is_preprint":false},{"year":2014,"finding":"Human mARC1 and mARC2 (MTARC2) catalyze the reduction of nitrite to nitric oxide (NO) through their molybdenum cofactor, forming an electron transfer chain with NADH, cytochrome b5, and NADH-dependent cytochrome b5 reductase. The active-site Cys-273 residue in mARC-1, which coordinates molybdenum binding, is required for NO formation (C273A mutation abolished activity). Replacement of molybdenum with tungsten abolished NO formation. NO formation rate increases ~3-fold at pH 6.5 vs 7.5.","method":"Reconstituted enzyme system in vitro, active-site mutagenesis (C273A), tungsten substitution, lentiviral mARC-1 expression in HEK cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, active-site mutagenesis, metal substitution, and cellular expression all converge on the same mechanism","pmids":["24500710"],"is_preprint":false},{"year":2011,"finding":"Pulsed EPR spectroscopy and 17O-labeling of mARC-2 (MTARC2) in the Mo(V) state revealed: an exchangeable equatorial hydroxyl ligand, a slowly exchangeable axial oxo ligand, and a non-exchangeable equatorial ligand that is most likely protein-derived (not an oxo group). The remaining two coordination positions are occupied by sulfur atoms from the molybdopterin cofactor.","method":"Continuous wave and pulsed EPR spectroscopy, 17O/D2O isotopic labeling, DFT calculations","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct structural/spectroscopic characterization of the active site with multiple spectroscopic approaches and DFT validation in a single rigorous study","pmids":["21916412"],"is_preprint":false},{"year":2012,"finding":"The mARC-containing three-component enzyme system (mARC1/mARC2 + cytochrome b5 + NADH cytochrome b5 reductase) catalyzes reductive detoxification of toxic and mutagenic N-hydroxylated nucleobases (N-hydroxylated purine and pyrimidine analogues). Both mARC isoforms reduce these substrates in vitro, with mARC1 being the more efficient isoform. N-reductive activity is most pronounced in enriched mitochondrial fractions across multiple tissues.","method":"Reconstituted in vitro assay with recombinant three-component system, subcellular fractionation of multiple tissues","journal":"Chemical research in toxicology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with recombinant enzymes, single lab, no cell-based confirmation for mARC2 specifically","pmids":["22924387"],"is_preprint":false},{"year":2010,"finding":"mARC1 and mARC2 (MTARC2) reduce N-hydroxy-sulfonamides (sulfohydroxamic acids) to sulfonamides using a reconstituted three-component enzyme system with cytochrome b5 and b5 reductase. N-hydroxy-valdecoxib is enzymatically reduced to its pharmacologically active metabolite valdecoxib by this system, demonstrating prodrug activation.","method":"Reconstituted enzyme system with recombinant human and native porcine enzymes, in vitro biochemical assay","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with both recombinant and native enzymes, single lab, single substrate class","pmids":["20699408"],"is_preprint":false},{"year":2014,"finding":"mARC2 (MTARC2) reduces N-oximes and N-hydroxyamidinohydrazones (guanoxabenz) in the reconstituted three-component enzyme system. However, N-oxides (amitriptyline-N-oxide, nicotinamide-N-oxide) are exclusively reduced by mARC1 and not by mARC2, indicating functional differences between the two isoforms beyond sequence.","method":"Reconstituted in vitro enzyme assay with recombinant mARC1 and mARC2","journal":"ChemMedChem","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with recombinant enzymes, single lab, establishes isoform-specific substrate selectivity","pmids":["25045021"],"is_preprint":false},{"year":2014,"finding":"Two nonsynonymous SNPs in MARC2 (MTARC2), G244S and C245W, result in statistically significant decreases in catalytic efficiency toward benzamidoxime compared to wild-type mARC-2, as measured in steady-state kinetic assays with recombinant proteins. All mARC-2 protein variants retain the ability to bind the molybdenum cofactor.","method":"Recombinant protein expression in E. coli, inductively coupled plasma mass spectrometry for Moco saturation, steady-state kinetic assays","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct enzymatic characterization of specific variants, single lab, multiple variants tested","pmids":["24423752"],"is_preprint":false},{"year":2014,"finding":"mARC-2 (MTARC2) reduces sulfamethoxazole hydroxylamine (SMX-HA). Knockdown of mARC-1 and mARC-2 in HEK-293 cells demonstrated that both reduce SMX-HA in cell metabolism. The recombinant human mARC-2 protein showed higher catalytic efficiency toward SMX-HA than mARC-1. Highest reduction rates were found in mitochondrial fractions and outer membrane vesicles.","method":"siRNA knockdown in HEK-293 cells, recombinant enzyme kinetics, subcellular fractionation with outer membrane vesicles","journal":"Chemical research in toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based knockdown combined with in vitro enzyme kinetics and subcellular fractionation, single lab","pmids":["25170804"],"is_preprint":false},{"year":2015,"finding":"mARC2 (MTARC2) specifically protects HeLa cells against apoptotic effects of the base analog N6-hydroxylaminopurine (HAP). RNAi-mediated knockdown of mARC2 (but not mARC1) increased HAP-induced apoptotic cell death and PARP cleavage, demonstrating a pivotal role for mARC2 in reductive detoxification of HAP in human cell metabolism.","method":"RNAi knockdown in HeLa cells, flow cytometric quantification of apoptosis, PARP cleavage detection by western blot","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockdown with two orthogonal apoptosis readouts, isoform-specific distinction established, single lab","pmids":["25713076"],"is_preprint":false},{"year":2015,"finding":"siRNA knockdown of mARC2 (MTARC2) in murine adipocytes had a statistically significant effect on diglyceride levels and fatty acid composition of triglycerides, with a trend toward reduced formation of most triglyceride and phospholipid species. Knockdown of mARC2 in adipocytes prevented ximelagatran-induced inhibition of mitochondrial respiration, indicating mARC2 is responsible for metabolic activation of ximelagatran into a mitotoxic metabolite.","method":"siRNA knockdown in differentiated murine adipocytes, lipidomics, Seahorse mitochondrial respiration assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown with lipidomic and functional metabolic readouts, single lab, multiple orthogonal endpoints","pmids":["26378779"],"is_preprint":false},{"year":2019,"finding":"MARC2 knockout mice showed significantly decreased reductase activity toward multiple N-oxygenated substrates, with only small residual activity attributable to MARC1 expression. MARC2 KO mice exhibited lower body weight, increased body temperature, decreased total cholesterol, increased glucose levels, and resistance to high-fat diet-induced obesity, establishing MARC2 as the primary enzyme responsible for N-reductive biotransformation and a regulator of energy homeostasis in mice.","method":"MARC2 knockout mouse model, in vivo and in vitro N-reductive activity assays, metabolic phenotyping on high-fat diet","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with multiple orthogonal phenotypic readouts (enzymatic activity, metabolic parameters, diet-induced obesity resistance), confirmed by in vitro assays","pmids":["31554661"],"is_preprint":false},{"year":2020,"finding":"MARC2 (MTARC2) suppresses hepatocellular carcinoma progression by regulating the protein expression level of p27. The Hippo signaling pathway and E3 ubiquitin ligase RNF123 are required for this process. MARC2 regulates expression of HNF4A via the Hippo signaling pathway, and HNF4A is recruited to the MARC2 promoter forming a feedback loop. MARC2 levels are downregulated by promoter methylation in HCC.","method":"In vitro and in vivo (xenograft) overexpression/knockdown studies, western blot for p27, reporter assays, ChIP for HNF4A binding, methylation analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and in vivo functional experiments with mechanistic pathway placement, single lab","pmids":["32811980"],"is_preprint":false},{"year":2023,"finding":"Human mARC1 and mARC2 (MTARC2) can reduce hydrogen peroxide (H2O2), the first identified mARC substrate without a nitrogen-oxygen bond. MTARC1 knockout HEK-293T cells showed increased sensitivity to H2O2, implying a role for mARC enzymes in the cellular response to oxidative stress.","method":"In vitro enzyme assay with recombinant mARC proteins, MTARC1 knockout HEK-293T cells with H2O2 sensitivity assay","journal":"Molecules (Basel, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro enzyme assay combined with cell-based knockout experiment, single lab, novel substrate class","pmids":["37687214"],"is_preprint":false},{"year":2022,"finding":"mARC1 and mARC2 (MTARC2) were quantified by targeted proteomics across human tissues. mARC2 abundance in the kidney was approximately 9-fold higher than mARC1 in paired liver-kidney samples, whereas hepatic mARC1 and mARC2 abundance was comparable. mARC2 is approximately 2.5-fold more abundant than hepatic levels in kidney S9 fraction, indicating isoform-specific differential tissue distribution.","method":"Targeted quantitative proteomics in pediatric and adult human tissue fractions (liver homogenate, total membrane fraction, S9 fractions)","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics across multiple tissue types and donor cohorts, establishes isoform-specific distribution","pmids":["34949674"],"is_preprint":false},{"year":2025,"finding":"MTARC2 interacts with SARS-CoV-2 Orf9b in bat cells and acts as a bat-enriched restriction factor. A single amino acid difference in Orf9b between SARS-CoV-2 and RaTG13 functions as a molecular switch: in bat cells, the RaTG13 variant of Orf9b has strengthened interaction with MTARC2, which limits coronavirus infection, whereas the SARS-CoV-2 variant preferentially binds Tom70 in human cells for immune evasion.","method":"Affinity purification-mass spectrometry (AP-MS) in human and bat cells, comparative PPI mapping, viral replication assays with single-residue Orf9b variants","journal":"Cell host & microbe","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — AP-MS interaction mapping combined with functional viral replication assays using defined genetic variants, single study","pmids":["42134328"],"is_preprint":false},{"year":2022,"finding":"Restoring expression of MARC2 (MTARC2) in hepatocellular carcinoma cells increased expression of HLA-C and B2M via PPARA-related lipid metabolism signaling pathways, facilitating tumor antigen presentation. MARC2 expression negatively correlated with multiple immune checkpoints, and downregulation of MARC2 was associated with differentiation of CD4+ T cells into regulatory T cells (Tregs).","method":"MARC2 overexpression in HCC cell lines, flow cytometry for T cell phenotyping, western blot and gene expression analysis for HLA-C, B2M, PPARA pathway","journal":"Frontiers in genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, correlative analyses with limited mechanistic validation of the PPARA-HLA pathway linkage","pmids":["35173763"],"is_preprint":false}],"current_model":"MTARC2 (mARC2/MOSC2) is a molybdenum cofactor-containing enzyme exclusively localized to the outer mitochondrial membrane, where it functions as the catalytic component of a three-protein N-reductive system (with CYB5B and NADH cytochrome b5 reductase) that reduces a broad range of N-hydroxylated compounds including amidoxime prodrugs, N-hydroxylated nucleobases, sulfohydroxamic acids, and nitrite (to NO); it is the dominant isoform for N-reductive biotransformation in mice, plays roles in lipid synthesis/energy homeostasis, protects cells from apoptosis induced by mutagenic base analogs via detoxification, can reduce hydrogen peroxide, and in bat cells acts as a restriction factor against coronavirus infection through direct interaction with viral Orf9b protein."},"narrative":{"mechanistic_narrative":"MTARC2 (mARC2/MOSC2) is a molybdenum cofactor-containing enzyme of the outer mitochondrial membrane that serves as the catalytic component of a three-protein N-reductive system, together with the mitochondrial cytochrome b5 isoform CYB5B and NADH cytochrome b5 reductase [PMID:22203676, PMID:23703616]. EPR and isotopic-labeling of the Mo(V) state define an active site in which the molybdenum carries an exchangeable equatorial hydroxyl, an axial oxo, a protein-derived equatorial ligand, and two sulfur atoms from the molybdopterin cofactor [PMID:21916412]; catalysis depends on the molybdenum center and a coordinating active-site cysteine, and on heme-loaded CYB5B as the obligate electron-transfer partner [PMID:23703616, PMID:24500710]. Through this electron chain MTARC2 reduces a broad range of N-hydroxylated substrates including amidoxime prodrugs, N-hydroxylated nucleobases, N-hydroxy-sulfonamides, and N-oximes, and reduces nitrite to nitric oxide, with isoform-specific selectivity distinguishing it from mARC1 [PMID:24500710, PMID:22924387, PMID:20699408, PMID:25045021, PMID:25170804]; it also reduces hydrogen peroxide, a substrate lacking a nitrogen–oxygen bond [PMID:37687214]. Cellular consequences of this activity include reductive detoxification that protects cells from apoptosis induced by the mutagenic base analog N6-hydroxylaminopurine [PMID:25713076] and metabolic activation of prodrugs and mitotoxic metabolites in adipocytes [PMID:26378779]. MTARC2 is the dominant N-reductive isoform in mice, where its loss reduces N-oxygenated substrate reduction and reprograms energy homeostasis, conferring resistance to high-fat-diet-induced obesity [PMID:31554661]. Beyond N-reduction, MTARC2 suppresses hepatocellular carcinoma progression via Hippo-pathway- and RNF123-dependent regulation of p27 and HNF4A [PMID:32811980], and in bat cells it acts as a restriction factor against coronavirus infection through interaction with the viral Orf9b protein [PMID:42134328].","teleology":[{"year":2011,"claim":"Established where MTARC2 acts and what it does at the cellular level, resolving its localization, its essential electron-transfer partner, and a physiological function.","evidence":"Subcellular fractionation, radiolabeled benzamidoxime binding, and siRNA knockdown with enzymatic and lipid-synthesis readouts in rat liver and 3T3-L1 adipocytes","pmids":["22203676"],"confidence":"High","gaps":["Did not resolve the catalytic mechanism at the molybdenum center","Functional partner CYB5B identified by knockdown but not reconstituted in vitro here"]},{"year":2011,"claim":"Defined the molybdenum active-site coordination geometry, providing the structural basis for the enzyme's redox chemistry.","evidence":"Continuous-wave and pulsed EPR with 17O/D2O labeling and DFT calculations on Mo(V)-state mARC2","pmids":["21916412"],"confidence":"High","gaps":["Identity of the protein-derived equatorial ligand not definitively assigned","No full crystal structure of the holoenzyme"]},{"year":2010,"claim":"Demonstrated that MTARC2 activates prodrugs by reducing N-hydroxy-sulfonamides, extending its substrate scope to pharmacologically relevant compounds.","evidence":"Reconstituted three-component enzyme system with recombinant human and native porcine enzymes","pmids":["20699408"],"confidence":"Medium","gaps":["Single substrate class","No cell-based confirmation"]},{"year":2012,"claim":"Showed the system reductively detoxifies mutagenic N-hydroxylated nucleobases, linking N-reduction to protection against genotoxic base analogs.","evidence":"Reconstituted in vitro assay with recombinant three-component system and subcellular fractionation across tissues","pmids":["22924387"],"confidence":"Medium","gaps":["mARC2-specific contribution not isolated in cells here","mARC1 reported as more efficient for these substrates"]},{"year":2013,"claim":"Confirmed in human cells that CYB5B (heme-dependent), not the microsomal CYB5A, is the obligate electron-transfer partner of the mARC N-reductase.","evidence":"Reciprocal RNAi knockdown in HEK-293 and HeLa, CYB5A knockout mice, and heme-free apo-CYB5 reconstitution","pmids":["23703616"],"confidence":"High","gaps":["Stoichiometry and assembly of the three-protein complex not resolved"]},{"year":2014,"claim":"Mapped the catalytic determinants of nitrite-to-NO reduction to the molybdenum cofactor and its coordinating cysteine, identifying a non-N-O-bond physiological function.","evidence":"Reconstituted enzyme system, C273A active-site mutagenesis, tungsten-for-molybdenum substitution, and cellular expression","pmids":["24500710"],"confidence":"High","gaps":["Cys mapping demonstrated in mARC1; equivalent in mARC2 inferred","Physiological relevance of NO output in vivo not established"]},{"year":2014,"claim":"Established isoform-specific substrate selectivity, distinguishing MTARC2's reductive repertoire from mARC1's (e.g., N-oxides reduced only by mARC1).","evidence":"Reconstituted in vitro assays comparing recombinant mARC1 and mARC2 across N-oximes, hydrazones, and N-oxides","pmids":["25045021"],"confidence":"Medium","gaps":["Structural basis of selectivity not defined","In vitro only"]},{"year":2014,"claim":"Showed that natural MTARC2 coding variants reduce catalytic efficiency without abolishing cofactor binding, defining functionally consequential polymorphisms.","evidence":"Recombinant G244S and C245W variants, ICP-MS Moco saturation, steady-state kinetics with benzamidoxime","pmids":["24423752"],"confidence":"Medium","gaps":["No in vivo or clinical correlation of variants","Single substrate tested"]},{"year":2014,"claim":"Demonstrated MTARC2 reduces the drug metabolite SMX-HA more efficiently than mARC1, linking the enzyme to xenobiotic detoxification in cells.","evidence":"siRNA knockdown in HEK-293, recombinant enzyme kinetics, and subcellular fractionation with outer membrane vesicles","pmids":["25170804"],"confidence":"Medium","gaps":["Single lab","In vivo relevance not tested"]},{"year":2015,"claim":"Connected MTARC2-specific reductive detoxification to cell survival by showing it protects against apoptosis from a mutagenic base analog.","evidence":"RNAi knockdown in HeLa with flow-cytometric apoptosis quantification and PARP cleavage western blot","pmids":["25713076"],"confidence":"Medium","gaps":["Isoform distinction shown but mechanism of mARC2 specificity unexplained","Single cell line"]},{"year":2015,"claim":"Linked MTARC2 activity to lipid composition and to bioactivation of a mitotoxic prodrug metabolite in adipocytes.","evidence":"siRNA knockdown in murine adipocytes with lipidomics and Seahorse mitochondrial respiration","pmids":["26378779"],"confidence":"Medium","gaps":["Mechanism connecting N-reductase activity to lipid metabolism not resolved","Trends not all statistically significant"]},{"year":2019,"claim":"Genetic knockout established MTARC2 as the primary N-reductive enzyme in mice and a regulator of whole-body energy homeostasis.","evidence":"MARC2 knockout mouse with in vivo/in vitro N-reductase assays and high-fat-diet metabolic phenotyping","pmids":["31554661"],"confidence":"High","gaps":["Molecular link between N-reductase activity and metabolic phenotype not defined","Mouse-to-human extrapolation untested"]},{"year":2020,"claim":"Placed MTARC2 in a tumor-suppressive pathway in hepatocellular carcinoma acting through Hippo signaling, RNF123, p27, and HNF4A.","evidence":"In vitro and xenograft overexpression/knockdown, p27 western blot, reporter and ChIP assays, promoter methylation analysis","pmids":["32811980"],"confidence":"Medium","gaps":["Connection between enzymatic activity and tumor suppression unestablished","Single lab"]},{"year":2022,"claim":"Quantified isoform-specific tissue distribution, showing MTARC2 dominance in kidney relative to mARC1.","evidence":"Targeted quantitative proteomics across human liver and kidney fractions in pediatric and adult cohorts","pmids":["34949674"],"confidence":"Medium","gaps":["Functional consequence of differential distribution not tested"]},{"year":2022,"claim":"Associated MTARC2 with tumor antigen presentation and immune phenotype in HCC via lipid-metabolism signaling.","evidence":"MARC2 overexpression in HCC lines with flow cytometry, expression analysis of HLA-C/B2M/PPARA","pmids":["35173763"],"confidence":"Low","gaps":["Correlative with limited mechanistic validation of the PPARA-HLA linkage","No in vivo confirmation"]},{"year":2023,"claim":"Extended MTARC2 substrate scope beyond N-O bonds by showing it reduces hydrogen peroxide, implicating it in oxidative-stress responses.","evidence":"In vitro recombinant enzyme assay and MTARC1 knockout HEK-293T H2O2 sensitivity assay","pmids":["37687214"],"confidence":"Medium","gaps":["Cellular sensitivity tested for MTARC1 knockout, not MTARC2-specific","Physiological significance unclear"]},{"year":2025,"claim":"Identified MTARC2 as a bat-enriched coronavirus restriction factor acting through interaction with viral Orf9b.","evidence":"AP-MS in human and bat cells with comparative PPI mapping and viral replication assays using single-residue Orf9b variants","pmids":["42134328"],"confidence":"Medium","gaps":["Mechanism of restriction downstream of Orf9b binding not defined","Whether enzymatic activity is involved unknown"]},{"year":null,"claim":"How MTARC2's outer-mitochondrial N-reductase chemistry mechanistically drives its diverse physiological roles — energy homeostasis, tumor suppression, and viral restriction — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No holoenzyme structure of the three-protein complex","No causal link between catalytic activity and metabolic/oncologic phenotypes","Mechanism of Orf9b-mediated coronavirus restriction undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,4,5,6,8,13]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[4,5,8]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,8]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[5,8,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[10,11]}],"complexes":[],"partners":["CYB5B","ORF9B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q969Z3","full_name":"Mitochondrial amidoxime reducing component 2","aliases":["Molybdenum cofactor sulfurase C-terminal domain-containing protein 2","MOSC domain-containing protein 2","Moco sulfurase C-terminal domain-containing protein 2"],"length_aa":335,"mass_kda":38.0,"function":"Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:21029045, PubMed:24423752). As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability (PubMed:21029045, PubMed:24423752). May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis (PubMed:21029045). Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction (PubMed:21029045)","subcellular_location":"Mitochondrion outer membrane; Peroxisome","url":"https://www.uniprot.org/uniprotkb/Q969Z3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MTARC2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1090,"dependency_fraction":0.0009174311926605505},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MTARC2","total_profiled":1310},"omim":[{"mim_id":"614127","title":"MITOCHONDRIAL AMIDOXIME-REDUCING COMPONENT 2; MTARC2","url":"https://www.omim.org/entry/614127"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"kidney","ntpm":123.2},{"tissue":"liver","ntpm":208.6}],"url":"https://www.proteinatlas.org/search/MTARC2"},"hgnc":{"alias_symbol":["FLJ20605"],"prev_symbol":["MOSC2","MARC2"]},"alphafold":{"accession":"Q969Z3","domains":[{"cath_id":"2.40.33.20","chopping":"52-335","consensus_level":"medium","plddt":97.532,"start":52,"end":335}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q969Z3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q969Z3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q969Z3-F1-predicted_aligned_error_v6.png","plddt_mean":91.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MTARC2","jax_strain_url":"https://www.jax.org/strain/search?query=MTARC2"},"sequence":{"accession":"Q969Z3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q969Z3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q969Z3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q969Z3"}},"corpus_meta":[{"pmid":"24500710","id":"PMC_24500710","title":"Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24500710","citation_count":130,"is_preprint":false},{"pmid":"21061036","id":"PMC_21061036","title":"Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors.","date":"2010","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21061036","citation_count":94,"is_preprint":false},{"pmid":"25270054","id":"PMC_25270054","title":"Identification of co-expression gene networks, regulatory genes and pathways for obesity based on adipose tissue RNA Sequencing in a porcine model.","date":"2014","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25270054","citation_count":87,"is_preprint":false},{"pmid":"23086957","id":"PMC_23086957","title":"The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23086957","citation_count":63,"is_preprint":false},{"pmid":"25425164","id":"PMC_25425164","title":"The mammalian molybdenum enzymes of mARC.","date":"2014","source":"Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25425164","citation_count":56,"is_preprint":false},{"pmid":"22203676","id":"PMC_22203676","title":"Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22203676","citation_count":51,"is_preprint":false},{"pmid":"22924387","id":"PMC_22924387","title":"The mitochondrial Amidoxime Reducing Component (mARC) is involved in detoxification of N-hydroxylated base analogues.","date":"2012","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22924387","citation_count":51,"is_preprint":false},{"pmid":"21942410","id":"PMC_21942410","title":"The fourth mammalian molybdenum enzyme mARC: current state of research.","date":"2011","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21942410","citation_count":46,"is_preprint":false},{"pmid":"23703616","id":"PMC_23703616","title":"The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23703616","citation_count":42,"is_preprint":false},{"pmid":"20699408","id":"PMC_20699408","title":"Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC.","date":"2010","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/20699408","citation_count":36,"is_preprint":false},{"pmid":"26378779","id":"PMC_26378779","title":"Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26378779","citation_count":28,"is_preprint":false},{"pmid":"25170804","id":"PMC_25170804","title":"Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).","date":"2014","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25170804","citation_count":26,"is_preprint":false},{"pmid":"25045021","id":"PMC_25045021","title":"The mitochondrial amidoxime reducing component (mARC): involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones.","date":"2014","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/25045021","citation_count":24,"is_preprint":false},{"pmid":"30520096","id":"PMC_30520096","title":"A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30520096","citation_count":21,"is_preprint":false},{"pmid":"31554661","id":"PMC_31554661","title":"Mitochondrial amidoxime-reducing component 2 (MARC2) has a significant role in N-reductive activity and energy metabolism.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31554661","citation_count":20,"is_preprint":false},{"pmid":"31878355","id":"PMC_31878355","title":"RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31878355","citation_count":20,"is_preprint":false},{"pmid":"29856598","id":"PMC_29856598","title":"Detoxification of Trimethylamine N-Oxide by the Mitochondrial Amidoxime Reducing Component mARC.","date":"2018","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29856598","citation_count":20,"is_preprint":false},{"pmid":"21916412","id":"PMC_21916412","title":"Structural studies of the molybdenum center of mitochondrial amidoxime reducing component (mARC) by pulsed EPR spectroscopy and 17O-labeling.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21916412","citation_count":18,"is_preprint":false},{"pmid":"32811980","id":"PMC_32811980","title":"A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32811980","citation_count":16,"is_preprint":false},{"pmid":"25713076","id":"PMC_25713076","title":"The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25713076","citation_count":16,"is_preprint":false},{"pmid":"24423752","id":"PMC_24423752","title":"Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.","date":"2014","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/24423752","citation_count":15,"is_preprint":false},{"pmid":"38437227","id":"PMC_38437227","title":"Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.","date":"2024","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38437227","citation_count":10,"is_preprint":false},{"pmid":"34012852","id":"PMC_34012852","title":"A neonate with molybdenum cofactor deficiency type B.","date":"2021","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34012852","citation_count":9,"is_preprint":false},{"pmid":"35173763","id":"PMC_35173763","title":"Downregulation of MARC2 Promotes Immune Escape and Is Associated With Immunosuppression of Hepatocellular Carcinoma.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35173763","citation_count":8,"is_preprint":false},{"pmid":"35700342","id":"PMC_35700342","title":"Enzyme Electrode Biosensors for N-Hydroxylated Prodrugs Incorporating the Mitochondrial Amidoxime Reducing Component.","date":"2022","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35700342","citation_count":8,"is_preprint":false},{"pmid":"33070307","id":"PMC_33070307","title":"Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.","date":"2020","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33070307","citation_count":6,"is_preprint":false},{"pmid":"37687214","id":"PMC_37687214","title":"Reduction of Hydrogen Peroxide by Human Mitochondrial Amidoxime Reducing Component Enzymes.","date":"2023","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37687214","citation_count":6,"is_preprint":false},{"pmid":"34949674","id":"PMC_34949674","title":"Interindividual Variability and Differential Tissue Abundance of Mitochondrial Amidoxime Reducing Component Enzymes in Humans.","date":"2021","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/34949674","citation_count":5,"is_preprint":false},{"pmid":"38010085","id":"PMC_38010085","title":"CIRC-MARC2 SILENCING PROTECTS HUMAN CARDIOMYOCYTES FROM HYPOXIA/REOXYGENATION-INDUCED INJURY BY MODULATING MIR-335-5P/TRPM7 AXIS.","date":"2023","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/38010085","citation_count":3,"is_preprint":false},{"pmid":"40437401","id":"PMC_40437401","title":"Western Diet and fecal microbiota transplantation alter phenotypic, liver fatty acids, and gut metagenomics and metabolomics in Mtarc2 knockout mice.","date":"2025","source":"Genes & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/40437401","citation_count":3,"is_preprint":false},{"pmid":"37855592","id":"PMC_37855592","title":"Probiotic Enterococcus faecalis surface-delivering key domain of EtMIC3 proteins: immunoprotective efficacies against Eimeria tenella infection in chickens.","date":"2023","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/37855592","citation_count":3,"is_preprint":false},{"pmid":"34070677","id":"PMC_34070677","title":"Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34070677","citation_count":2,"is_preprint":false},{"pmid":"39711797","id":"PMC_39711797","title":"Transcriptome-wide association studies identify candidate genes for carcass and meat traits in meat rabbits.","date":"2024","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/39711797","citation_count":2,"is_preprint":false},{"pmid":"39957063","id":"PMC_39957063","title":"Exercise-Induced Changes in Hemodynamics, Hormones, Electrolytes, and Inflammatory Markers in Veteran Athletes with and without Coronary Atherosclerosis.","date":"2025","source":"Medicine and science in sports and exercise","url":"https://pubmed.ncbi.nlm.nih.gov/39957063","citation_count":2,"is_preprint":false},{"pmid":"40766693","id":"PMC_40766693","title":"Coronavirus protein interaction mapping in bat and human cells identifies molecular and genetic switches for immune evasion and replication.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40766693","citation_count":1,"is_preprint":false},{"pmid":"42134328","id":"PMC_42134328","title":"Coronavirus protein interaction mapping in bat and human cells reveals network rewiring governing immune evasion and zoonotic potential.","date":"2026","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/42134328","citation_count":0,"is_preprint":false},{"pmid":"41639642","id":"PMC_41639642","title":"Sex- and mouse strain-related differences in body weight gain, composition of the gut microbiota, and levels of selected metabolites in response to a Western-style diet.","date":"2026","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/41639642","citation_count":0,"is_preprint":false},{"pmid":"17646147","id":"PMC_17646147","title":"[Analysis of microsatellite markers on four chromosomes in F2 design pig resource family].","date":"2007","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/17646147","citation_count":0,"is_preprint":false},{"pmid":"40924252","id":"PMC_40924252","title":"Landscape genomics analysis reveals the genetic basis underlying cashmere goats and dairy goats adaptation to frigid environments.","date":"2025","source":"Stress biology","url":"https://pubmed.ncbi.nlm.nih.gov/40924252","citation_count":0,"is_preprint":false},{"pmid":"41641916","id":"PMC_41641916","title":"MTARC1 Inactivation Remodels Lipid Droplets to Protect Against Metabolic Fatty Liver Disease.","date":"2026","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/41641916","citation_count":0,"is_preprint":false},{"pmid":"39994562","id":"PMC_39994562","title":"A comparison of genome-wide association analyses of persistent symptoms after Lyme disease, fibromyalgia, and myalgic encephalomyelitis - chronic fatigue syndrome.","date":"2025","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39994562","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24208,"output_tokens":4747,"usd":0.071915,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12867,"output_tokens":4637,"usd":0.09013,"stage2_stop_reason":"end_turn"},"total_usd":0.162045,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"MOSC2 (MTARC2) is exclusively localized to the outer mitochondrial membrane in rat liver, as demonstrated by subcellular fractionation of purified outer mitochondrial membranes. Direct binding of a radiolabeled benzamidoxime substrate to MOSC2 was shown. siRNA-mediated knockdown of MOSC2 and mitochondrial cytochrome b5 type B (CYB5B) significantly inhibited amidoxime reductase activity in differentiated 3T3-L1 adipocytes, whereas knockdown of MOSC1, CYB5A, CYB5R1, CYB5R2, or CYB5R3 had no effect. Knockdown of MOSC2 caused impaired lipid synthesis in adipocytes.\",\n      \"method\": \"Subcellular fractionation, radiolabeled substrate binding assay, siRNA knockdown with enzymatic activity readout and lipid synthesis measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (fractionation, direct substrate binding, siRNA knockdown with functional readouts) in a single rigorous study establishing localization, binding partner identity, and cellular function\",\n      \"pmids\": [\"22203676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Both mARC1 and mARC2 (MTARC2) are capable of reducing N-hydroxylated substrates (amidoximes) in cellular metabolism, as demonstrated by RNAi knockdown in two human cell lines (HEK-293 and HeLa). The mitochondrial isoform of cytochrome b5 (CYB5B) is an essential electron transport component of the mARC-containing N-reductase system in human cells; the microsomal isoform CYB5A does not participate. The contribution of CYB5B strictly depends on heme, as shown with heme-free apo-CYB5.\",\n      \"method\": \"RNAi knockdown in human cell lines (HEK-293, HeLa), CYB5A knockout mice, heme-free apo-CYB5 reconstitution assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal knockdown experiments in two cell lines plus knockout mouse plus biochemical reconstitution with functional readouts\",\n      \"pmids\": [\"23703616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Human mARC1 and mARC2 (MTARC2) catalyze the reduction of nitrite to nitric oxide (NO) through their molybdenum cofactor, forming an electron transfer chain with NADH, cytochrome b5, and NADH-dependent cytochrome b5 reductase. The active-site Cys-273 residue in mARC-1, which coordinates molybdenum binding, is required for NO formation (C273A mutation abolished activity). Replacement of molybdenum with tungsten abolished NO formation. NO formation rate increases ~3-fold at pH 6.5 vs 7.5.\",\n      \"method\": \"Reconstituted enzyme system in vitro, active-site mutagenesis (C273A), tungsten substitution, lentiviral mARC-1 expression in HEK cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, active-site mutagenesis, metal substitution, and cellular expression all converge on the same mechanism\",\n      \"pmids\": [\"24500710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pulsed EPR spectroscopy and 17O-labeling of mARC-2 (MTARC2) in the Mo(V) state revealed: an exchangeable equatorial hydroxyl ligand, a slowly exchangeable axial oxo ligand, and a non-exchangeable equatorial ligand that is most likely protein-derived (not an oxo group). The remaining two coordination positions are occupied by sulfur atoms from the molybdopterin cofactor.\",\n      \"method\": \"Continuous wave and pulsed EPR spectroscopy, 17O/D2O isotopic labeling, DFT calculations\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct structural/spectroscopic characterization of the active site with multiple spectroscopic approaches and DFT validation in a single rigorous study\",\n      \"pmids\": [\"21916412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The mARC-containing three-component enzyme system (mARC1/mARC2 + cytochrome b5 + NADH cytochrome b5 reductase) catalyzes reductive detoxification of toxic and mutagenic N-hydroxylated nucleobases (N-hydroxylated purine and pyrimidine analogues). Both mARC isoforms reduce these substrates in vitro, with mARC1 being the more efficient isoform. N-reductive activity is most pronounced in enriched mitochondrial fractions across multiple tissues.\",\n      \"method\": \"Reconstituted in vitro assay with recombinant three-component system, subcellular fractionation of multiple tissues\",\n      \"journal\": \"Chemical research in toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with recombinant enzymes, single lab, no cell-based confirmation for mARC2 specifically\",\n      \"pmids\": [\"22924387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"mARC1 and mARC2 (MTARC2) reduce N-hydroxy-sulfonamides (sulfohydroxamic acids) to sulfonamides using a reconstituted three-component enzyme system with cytochrome b5 and b5 reductase. N-hydroxy-valdecoxib is enzymatically reduced to its pharmacologically active metabolite valdecoxib by this system, demonstrating prodrug activation.\",\n      \"method\": \"Reconstituted enzyme system with recombinant human and native porcine enzymes, in vitro biochemical assay\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with both recombinant and native enzymes, single lab, single substrate class\",\n      \"pmids\": [\"20699408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"mARC2 (MTARC2) reduces N-oximes and N-hydroxyamidinohydrazones (guanoxabenz) in the reconstituted three-component enzyme system. However, N-oxides (amitriptyline-N-oxide, nicotinamide-N-oxide) are exclusively reduced by mARC1 and not by mARC2, indicating functional differences between the two isoforms beyond sequence.\",\n      \"method\": \"Reconstituted in vitro enzyme assay with recombinant mARC1 and mARC2\",\n      \"journal\": \"ChemMedChem\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with recombinant enzymes, single lab, establishes isoform-specific substrate selectivity\",\n      \"pmids\": [\"25045021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Two nonsynonymous SNPs in MARC2 (MTARC2), G244S and C245W, result in statistically significant decreases in catalytic efficiency toward benzamidoxime compared to wild-type mARC-2, as measured in steady-state kinetic assays with recombinant proteins. All mARC-2 protein variants retain the ability to bind the molybdenum cofactor.\",\n      \"method\": \"Recombinant protein expression in E. coli, inductively coupled plasma mass spectrometry for Moco saturation, steady-state kinetic assays\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct enzymatic characterization of specific variants, single lab, multiple variants tested\",\n      \"pmids\": [\"24423752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"mARC-2 (MTARC2) reduces sulfamethoxazole hydroxylamine (SMX-HA). Knockdown of mARC-1 and mARC-2 in HEK-293 cells demonstrated that both reduce SMX-HA in cell metabolism. The recombinant human mARC-2 protein showed higher catalytic efficiency toward SMX-HA than mARC-1. Highest reduction rates were found in mitochondrial fractions and outer membrane vesicles.\",\n      \"method\": \"siRNA knockdown in HEK-293 cells, recombinant enzyme kinetics, subcellular fractionation with outer membrane vesicles\",\n      \"journal\": \"Chemical research in toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based knockdown combined with in vitro enzyme kinetics and subcellular fractionation, single lab\",\n      \"pmids\": [\"25170804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"mARC2 (MTARC2) specifically protects HeLa cells against apoptotic effects of the base analog N6-hydroxylaminopurine (HAP). RNAi-mediated knockdown of mARC2 (but not mARC1) increased HAP-induced apoptotic cell death and PARP cleavage, demonstrating a pivotal role for mARC2 in reductive detoxification of HAP in human cell metabolism.\",\n      \"method\": \"RNAi knockdown in HeLa cells, flow cytometric quantification of apoptosis, PARP cleavage detection by western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockdown with two orthogonal apoptosis readouts, isoform-specific distinction established, single lab\",\n      \"pmids\": [\"25713076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"siRNA knockdown of mARC2 (MTARC2) in murine adipocytes had a statistically significant effect on diglyceride levels and fatty acid composition of triglycerides, with a trend toward reduced formation of most triglyceride and phospholipid species. Knockdown of mARC2 in adipocytes prevented ximelagatran-induced inhibition of mitochondrial respiration, indicating mARC2 is responsible for metabolic activation of ximelagatran into a mitotoxic metabolite.\",\n      \"method\": \"siRNA knockdown in differentiated murine adipocytes, lipidomics, Seahorse mitochondrial respiration assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown with lipidomic and functional metabolic readouts, single lab, multiple orthogonal endpoints\",\n      \"pmids\": [\"26378779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MARC2 knockout mice showed significantly decreased reductase activity toward multiple N-oxygenated substrates, with only small residual activity attributable to MARC1 expression. MARC2 KO mice exhibited lower body weight, increased body temperature, decreased total cholesterol, increased glucose levels, and resistance to high-fat diet-induced obesity, establishing MARC2 as the primary enzyme responsible for N-reductive biotransformation and a regulator of energy homeostasis in mice.\",\n      \"method\": \"MARC2 knockout mouse model, in vivo and in vitro N-reductive activity assays, metabolic phenotyping on high-fat diet\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with multiple orthogonal phenotypic readouts (enzymatic activity, metabolic parameters, diet-induced obesity resistance), confirmed by in vitro assays\",\n      \"pmids\": [\"31554661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MARC2 (MTARC2) suppresses hepatocellular carcinoma progression by regulating the protein expression level of p27. The Hippo signaling pathway and E3 ubiquitin ligase RNF123 are required for this process. MARC2 regulates expression of HNF4A via the Hippo signaling pathway, and HNF4A is recruited to the MARC2 promoter forming a feedback loop. MARC2 levels are downregulated by promoter methylation in HCC.\",\n      \"method\": \"In vitro and in vivo (xenograft) overexpression/knockdown studies, western blot for p27, reporter assays, ChIP for HNF4A binding, methylation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and in vivo functional experiments with mechanistic pathway placement, single lab\",\n      \"pmids\": [\"32811980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Human mARC1 and mARC2 (MTARC2) can reduce hydrogen peroxide (H2O2), the first identified mARC substrate without a nitrogen-oxygen bond. MTARC1 knockout HEK-293T cells showed increased sensitivity to H2O2, implying a role for mARC enzymes in the cellular response to oxidative stress.\",\n      \"method\": \"In vitro enzyme assay with recombinant mARC proteins, MTARC1 knockout HEK-293T cells with H2O2 sensitivity assay\",\n      \"journal\": \"Molecules (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro enzyme assay combined with cell-based knockout experiment, single lab, novel substrate class\",\n      \"pmids\": [\"37687214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"mARC1 and mARC2 (MTARC2) were quantified by targeted proteomics across human tissues. mARC2 abundance in the kidney was approximately 9-fold higher than mARC1 in paired liver-kidney samples, whereas hepatic mARC1 and mARC2 abundance was comparable. mARC2 is approximately 2.5-fold more abundant than hepatic levels in kidney S9 fraction, indicating isoform-specific differential tissue distribution.\",\n      \"method\": \"Targeted quantitative proteomics in pediatric and adult human tissue fractions (liver homogenate, total membrane fraction, S9 fractions)\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics across multiple tissue types and donor cohorts, establishes isoform-specific distribution\",\n      \"pmids\": [\"34949674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MTARC2 interacts with SARS-CoV-2 Orf9b in bat cells and acts as a bat-enriched restriction factor. A single amino acid difference in Orf9b between SARS-CoV-2 and RaTG13 functions as a molecular switch: in bat cells, the RaTG13 variant of Orf9b has strengthened interaction with MTARC2, which limits coronavirus infection, whereas the SARS-CoV-2 variant preferentially binds Tom70 in human cells for immune evasion.\",\n      \"method\": \"Affinity purification-mass spectrometry (AP-MS) in human and bat cells, comparative PPI mapping, viral replication assays with single-residue Orf9b variants\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — AP-MS interaction mapping combined with functional viral replication assays using defined genetic variants, single study\",\n      \"pmids\": [\"42134328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Restoring expression of MARC2 (MTARC2) in hepatocellular carcinoma cells increased expression of HLA-C and B2M via PPARA-related lipid metabolism signaling pathways, facilitating tumor antigen presentation. MARC2 expression negatively correlated with multiple immune checkpoints, and downregulation of MARC2 was associated with differentiation of CD4+ T cells into regulatory T cells (Tregs).\",\n      \"method\": \"MARC2 overexpression in HCC cell lines, flow cytometry for T cell phenotyping, western blot and gene expression analysis for HLA-C, B2M, PPARA pathway\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, correlative analyses with limited mechanistic validation of the PPARA-HLA pathway linkage\",\n      \"pmids\": [\"35173763\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MTARC2 (mARC2/MOSC2) is a molybdenum cofactor-containing enzyme exclusively localized to the outer mitochondrial membrane, where it functions as the catalytic component of a three-protein N-reductive system (with CYB5B and NADH cytochrome b5 reductase) that reduces a broad range of N-hydroxylated compounds including amidoxime prodrugs, N-hydroxylated nucleobases, sulfohydroxamic acids, and nitrite (to NO); it is the dominant isoform for N-reductive biotransformation in mice, plays roles in lipid synthesis/energy homeostasis, protects cells from apoptosis induced by mutagenic base analogs via detoxification, can reduce hydrogen peroxide, and in bat cells acts as a restriction factor against coronavirus infection through direct interaction with viral Orf9b protein.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MTARC2 (mARC2/MOSC2) is a molybdenum cofactor-containing enzyme of the outer mitochondrial membrane that serves as the catalytic component of a three-protein N-reductive system, together with the mitochondrial cytochrome b5 isoform CYB5B and NADH cytochrome b5 reductase [#0, #1]. EPR and isotopic-labeling of the Mo(V) state define an active site in which the molybdenum carries an exchangeable equatorial hydroxyl, an axial oxo, a protein-derived equatorial ligand, and two sulfur atoms from the molybdopterin cofactor [#3]; catalysis depends on the molybdenum center and a coordinating active-site cysteine, and on heme-loaded CYB5B as the obligate electron-transfer partner [#1, #2]. Through this electron chain MTARC2 reduces a broad range of N-hydroxylated substrates including amidoxime prodrugs, N-hydroxylated nucleobases, N-hydroxy-sulfonamides, and N-oximes, and reduces nitrite to nitric oxide, with isoform-specific selectivity distinguishing it from mARC1 [#2, #4, #5, #6, #8]; it also reduces hydrogen peroxide, a substrate lacking a nitrogen–oxygen bond [#13]. Cellular consequences of this activity include reductive detoxification that protects cells from apoptosis induced by the mutagenic base analog N6-hydroxylaminopurine [#9] and metabolic activation of prodrugs and mitotoxic metabolites in adipocytes [#10]. MTARC2 is the dominant N-reductive isoform in mice, where its loss reduces N-oxygenated substrate reduction and reprograms energy homeostasis, conferring resistance to high-fat-diet-induced obesity [#11]. Beyond N-reduction, MTARC2 suppresses hepatocellular carcinoma progression via Hippo-pathway- and RNF123-dependent regulation of p27 and HNF4A [#12], and in bat cells it acts as a restriction factor against coronavirus infection through interaction with the viral Orf9b protein [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Established where MTARC2 acts and what it does at the cellular level, resolving its localization, its essential electron-transfer partner, and a physiological function.\",\n      \"evidence\": \"Subcellular fractionation, radiolabeled benzamidoxime binding, and siRNA knockdown with enzymatic and lipid-synthesis readouts in rat liver and 3T3-L1 adipocytes\",\n      \"pmids\": [\"22203676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the catalytic mechanism at the molybdenum center\", \"Functional partner CYB5B identified by knockdown but not reconstituted in vitro here\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the molybdenum active-site coordination geometry, providing the structural basis for the enzyme's redox chemistry.\",\n      \"evidence\": \"Continuous-wave and pulsed EPR with 17O/D2O labeling and DFT calculations on Mo(V)-state mARC2\",\n      \"pmids\": [\"21916412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protein-derived equatorial ligand not definitively assigned\", \"No full crystal structure of the holoenzyme\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that MTARC2 activates prodrugs by reducing N-hydroxy-sulfonamides, extending its substrate scope to pharmacologically relevant compounds.\",\n      \"evidence\": \"Reconstituted three-component enzyme system with recombinant human and native porcine enzymes\",\n      \"pmids\": [\"20699408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single substrate class\", \"No cell-based confirmation\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed the system reductively detoxifies mutagenic N-hydroxylated nucleobases, linking N-reduction to protection against genotoxic base analogs.\",\n      \"evidence\": \"Reconstituted in vitro assay with recombinant three-component system and subcellular fractionation across tissues\",\n      \"pmids\": [\"22924387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mARC2-specific contribution not isolated in cells here\", \"mARC1 reported as more efficient for these substrates\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Confirmed in human cells that CYB5B (heme-dependent), not the microsomal CYB5A, is the obligate electron-transfer partner of the mARC N-reductase.\",\n      \"evidence\": \"Reciprocal RNAi knockdown in HEK-293 and HeLa, CYB5A knockout mice, and heme-free apo-CYB5 reconstitution\",\n      \"pmids\": [\"23703616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly of the three-protein complex not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the catalytic determinants of nitrite-to-NO reduction to the molybdenum cofactor and its coordinating cysteine, identifying a non-N-O-bond physiological function.\",\n      \"evidence\": \"Reconstituted enzyme system, C273A active-site mutagenesis, tungsten-for-molybdenum substitution, and cellular expression\",\n      \"pmids\": [\"24500710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cys mapping demonstrated in mARC1; equivalent in mARC2 inferred\", \"Physiological relevance of NO output in vivo not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established isoform-specific substrate selectivity, distinguishing MTARC2's reductive repertoire from mARC1's (e.g., N-oxides reduced only by mARC1).\",\n      \"evidence\": \"Reconstituted in vitro assays comparing recombinant mARC1 and mARC2 across N-oximes, hydrazones, and N-oxides\",\n      \"pmids\": [\"25045021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of selectivity not defined\", \"In vitro only\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that natural MTARC2 coding variants reduce catalytic efficiency without abolishing cofactor binding, defining functionally consequential polymorphisms.\",\n      \"evidence\": \"Recombinant G244S and C245W variants, ICP-MS Moco saturation, steady-state kinetics with benzamidoxime\",\n      \"pmids\": [\"24423752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo or clinical correlation of variants\", \"Single substrate tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated MTARC2 reduces the drug metabolite SMX-HA more efficiently than mARC1, linking the enzyme to xenobiotic detoxification in cells.\",\n      \"evidence\": \"siRNA knockdown in HEK-293, recombinant enzyme kinetics, and subcellular fractionation with outer membrane vesicles\",\n      \"pmids\": [\"25170804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected MTARC2-specific reductive detoxification to cell survival by showing it protects against apoptosis from a mutagenic base analog.\",\n      \"evidence\": \"RNAi knockdown in HeLa with flow-cytometric apoptosis quantification and PARP cleavage western blot\",\n      \"pmids\": [\"25713076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Isoform distinction shown but mechanism of mARC2 specificity unexplained\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked MTARC2 activity to lipid composition and to bioactivation of a mitotoxic prodrug metabolite in adipocytes.\",\n      \"evidence\": \"siRNA knockdown in murine adipocytes with lipidomics and Seahorse mitochondrial respiration\",\n      \"pmids\": [\"26378779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting N-reductase activity to lipid metabolism not resolved\", \"Trends not all statistically significant\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Genetic knockout established MTARC2 as the primary N-reductive enzyme in mice and a regulator of whole-body energy homeostasis.\",\n      \"evidence\": \"MARC2 knockout mouse with in vivo/in vitro N-reductase assays and high-fat-diet metabolic phenotyping\",\n      \"pmids\": [\"31554661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between N-reductase activity and metabolic phenotype not defined\", \"Mouse-to-human extrapolation untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed MTARC2 in a tumor-suppressive pathway in hepatocellular carcinoma acting through Hippo signaling, RNF123, p27, and HNF4A.\",\n      \"evidence\": \"In vitro and xenograft overexpression/knockdown, p27 western blot, reporter and ChIP assays, promoter methylation analysis\",\n      \"pmids\": [\"32811980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between enzymatic activity and tumor suppression unestablished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Quantified isoform-specific tissue distribution, showing MTARC2 dominance in kidney relative to mARC1.\",\n      \"evidence\": \"Targeted quantitative proteomics across human liver and kidney fractions in pediatric and adult cohorts\",\n      \"pmids\": [\"34949674\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of differential distribution not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Associated MTARC2 with tumor antigen presentation and immune phenotype in HCC via lipid-metabolism signaling.\",\n      \"evidence\": \"MARC2 overexpression in HCC lines with flow cytometry, expression analysis of HLA-C/B2M/PPARA\",\n      \"pmids\": [\"35173763\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlative with limited mechanistic validation of the PPARA-HLA linkage\", \"No in vivo confirmation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended MTARC2 substrate scope beyond N-O bonds by showing it reduces hydrogen peroxide, implicating it in oxidative-stress responses.\",\n      \"evidence\": \"In vitro recombinant enzyme assay and MTARC1 knockout HEK-293T H2O2 sensitivity assay\",\n      \"pmids\": [\"37687214\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular sensitivity tested for MTARC1 knockout, not MTARC2-specific\", \"Physiological significance unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified MTARC2 as a bat-enriched coronavirus restriction factor acting through interaction with viral Orf9b.\",\n      \"evidence\": \"AP-MS in human and bat cells with comparative PPI mapping and viral replication assays using single-residue Orf9b variants\",\n      \"pmids\": [\"42134328\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of restriction downstream of Orf9b binding not defined\", \"Whether enzymatic activity is involved unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MTARC2's outer-mitochondrial N-reductase chemistry mechanistically drives its diverse physiological roles — energy homeostasis, tumor suppression, and viral restriction — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No holoenzyme structure of the three-protein complex\", \"No causal link between catalytic activity and metabolic/oncologic phenotypes\", \"Mechanism of Orf9b-mediated coronavirus restriction undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 4, 5, 6, 8, 13]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [4, 5, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [5, 8, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CYB5B\", \"ORF9B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}